Genentech 2Q Revenues: $3.0 billion (+37%) 2Q Earnings: $747 million (+41%) YTD Revenues: $5.8 billion (+40%) YTD Earnings: $1.5 billion (+53%) Comments: U.S. product sales were $2.1 billion in the quarter, up 25%. Rituxan sales were $582 million, up 11% and Avastin sales were $564 million, up 33%. Royalty revenues were $484 million in the quarter and included approximately $65 million in one-time revenues from a new collaboration agreement, which included three years’...